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Abstract
Background: Aberrant DNA methylation leads to loss of heterozygosity (LOH) or loss of imprinting (LOI) as the first
hit during human carcinogenesis. Recently we developed a new high-throughput, high-resolution DNA
methylation analysis method, bisulphite PCR-Luminex (BPL), using sperm DNA and demonstrated the effectiveness
of this novel approach in rapidly identifying methylation errors.
Results: In the current study, we applied the BPL method to the analysis of DNA methylation for identification of
prognostic panels of DNA methylation cancer biomarkers of imprinted genes. We found that the BPL method
precisely quantified the methylation status of specific DNA regions in somatic cells. We found a higher frequency
of LOI than LOH. LOI at IGF2, PEG1 and H19 were frequent alterations, with a tendency to show a more
hypermethylated state. We detected changes in DNA methylation as an early event in ovarian cancer. The degree
of LOI (LOH) was associated with altered DNA methylation at IGF2/H19 and PEG1.
Conclusions: The relative ease of BPL method provides a practical method for use within a clinical setting. We
suggest that DNA methylation of H19 and PEG1 differentially methylated regions (DMRs) may provide novel
biomarkers useful for screening, diagnosis and, potentially, for improving the clinical management of women with
human ovarian cancer.
Keywords: Genomic imprinting, Ovarian cancer, DNA methylation, Bisulphite PCR-Luminex(BPL)method, LOI (loss of
imprinting)
Background
Human ovarian cancer (HOC) is the leading cause of
death from gynecological malignancies, primarily due to
the lateness of detection when the cancer is already at an
advanced stage. Effective screening protocols for early
stages are not currently available. HOC is characterized
by complex genetic and epigenetic alterations, including
loss of heterozygosity (LOH) and loss of imprinting
(LOI) [1,2]. Such alterations are presumed to represent
the second hit, according to Knudson’st w o - h i th y p o t h -
esis (OMIM #167000) [3]. However, alterations in DNA
methylation can also occur as the first hit during human
carcinogenesis [4].
For childhood cancers such as retinoblastoma (OMIM
#180200), Wilms’ tumor (OMIM #194070) and osteosar-
coma (OMIM #259500), changes primarily occur on the
paternal allele first, followed by a second hit on the mater-
nal allele [5,6]. Complete hydatidiform moles, which are of
androgenetic or paternal origin, are characterized by
malignant transformation whereas ovarian teratomas,
which are of parthenogenetic or maternal origin, are
benign [7,8]. These observations suggest a role for altered
genomic imprinting in the malignant transformation
process.
Alterations in the expression of imprinted genes
represent one of the most common changes seen in
cancer [9,10]. Some imprinted genes, including H19
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[14] and ZAC [15], are known to act, or strongly impli-
cated to act, as tumor suppressor genes (TSGs). The
monoallelic expression of imprinted genes is reliant on
epigenetic mechanisms, most notably DNA methylation,
which initiates the imprinting process in the male and
female germlines at discrete locations termed differen-
tially methylated regions (DMRs) [16]. Imprinted
domains generally contain several genes displaying
allele-specific expression and these DMRs, which can be
located over the promoter of a protein coding gene or
the promoter of a functional non-coding RNA or within
intergenic regions, are known to control imprinted gene
expression within the domain, acting as imprinting cen-
ters or imprint control regions [17]. We recently devel-
oped a new high-throughput, high-resolution DNA
methylation analysis method called bisulphite PCR-Lumi-
nex (BPL) for the rapid analysis of DNA methylation [18].
In this study, we applied this method to 21 HOC cell
lines and 74 HOC tissues to efficiently and accurately
determine the methylation status of DMRs at eight
imprinted loci, six of which contained TSGs. To deter-
mine whether abnormal methylation of these DMRs acts
as an indicator for potential LOH and/or LOI, we also
examined the association between abnormal hypermethy-
lation and LOI or LOH. We found a higher frequency of
LOI than LOH. LOI at IGF2, PEG1 and H19 was a fre-
quent alteration, with a tendency to show a more hyper-
methylated status. The degrees of LOI and altered DNA
methylation were similar among histology, progression
and tumor grades. This suggests that DNA methylation
of the H19 and PEG1 DMRs may provide novel biomar-
kers useful for screening, diagnosis and, potentially, for
improving the clinical management of women with HOC.
Results
Frequencies of the 8 imprinted gene profiles in HOC
We first determined whether the ovarian malignancies
showed LOH by comparing the restriction fragment
length polymorphism (RFLP) patterns of normal lympho-
cyte DNA and 74 matching primary HOC DNA samples.
Samples where RFLPs were present in the lymphocyte
DNA sample but absent or with an altered ratio in the
tumor sample were considered to exhibit LOH in the
regions of 8 imprinted genes (H19, IGF2, KCNQ1, LIT1,
GTL2, PEG1, PEG3 and NDN). The average percentage of
heterozygosity was 48.0% (16.2-58.5%). We found only 14
cases of LOH in the 8 imprinted genes in the 74 HOC
samples we analysed (Table 1). The most frequent gene
with LOH was IGF2 (9.0%, 3/33), followed by PEG1 (8.1%,
3/37) and GTL2 (7.1%, 3/42). LOH of NDN and LOT1 was
not detected (0/31 and 0/12). The samples with LOH were
not from the same cases (Additional file 1: Table 1).
We next performed RT-PCR and RFLP analysis to iden-
tify the samples of LOI without LOH. The frequency of
LOI was higher than that of LOH for all 8 imprinted
genes and we found a total of 46 cases of LOI (Table 1,
Additional file 1: Table S1). The most frequent sites of
LOI were PEG1 (45.9%, 17/37), IGF2 (45.4%, 15/33) and
H19 (29.2%, 12/41). NDN had the lowest frequency. In 19
of the 46 cases, the abnormal gene expression pattern was
apparent at two or more imprinted loci. A normal
imprinting pattern, maintenance of imprint (MOI), was
most frequent in NDN (93.5%, 29/31). ND (not deter-
mined) means no amplification of RT-PCR at 3 times in
several samples, perhaps indicating low expression of the
genes. In 9 of the 14 LOH cases, LOI was also found in at
least one gene. In HOC cell lines, LOI was found in 2 of 3
informative cases for IGF2, and 3 of 9 cases for PEG1.W e
did not find any LOH or LOI in 7 normal ovarian surface
tissues and 4 normal cell lines. We compared patients’
ages, progression, histology and tumor grades with
imprinted gene expression pattern profiles. Patients with
L O Ih a dat e n d e n c yt ob ey o u n g e rt h a np a t i e n t sw i t h
LOH (mean ages for LOH and LOI: 55.0 ± 7.4 and 47.7 ±
6.9, respectively), but the difference was not statistically
significant by ANOVA, and no other correlations were
apparent.
Analysis of the methylation status of DMRs in ovarian
cancers by the BPL method
The proof-of principle experiment of the BPL method has
been described in detail [18]. Briefly, bisulphite-DNA can
be used to distinguish between methylation and non-
methylation status in the genome, e.g. cytosine and uracil.
The BPL method can determine one base substitution by
specific hybridization and detect the ratio of methylation
to non-methylation. We examined the quality of the BPL
method in spermatic DNA, which should show 100%
methylation of the paternally methylated DMRs: ZDBF2,
H19 and GTL2, whereas the maternally methylated DMRs:
PEG1, ZAC, SNRPN, PEG3 and LIT1 are non-methylated.
We applied the classic methylation assay COBRA techni-
que and our recently devised BPL method to the DNA of
7 normal ovarian surface epithelium tissues, 4 primary
cultures of normal human ovarian surface epithelium
(OSE1-4) and 21 HOC cell lines, and performed statistical
analysis with Spearman’s and Pearson’s rank correlations.
For all 8 DMRs a good correlation was found between
these two methods (Figure 1, Table 2, Additional file 2:
Figure S1).
We next determined the methylation status of the 8
DMRs from the 74 samples of primary ovarian cancer tis-
sue by the BPL method. Overall, we compared the average
DNA methylation status of cancer and normal samples for
each DMR and found that PEG1 from ovarian cancers was
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tissues (normal, 30.7% ± 15.1: HOC, 45.9% ± 15.5)
(Table 3). The numbers of cancer tissue cases with
hypermethylation above the range of the methylation
rates in the normal ovarian surface epithelium were 17
for H19,2 1f o rGTL2,2 1f o rZDBF2,a n d1 4f o rPEG1
(Table 3). On the other hand, hypomethylation below the
methylation level of normal ovarian tissues was found in
15 cases for GTL2 and 23 for ZDBF2.W ed i dn o t
observe a significant difference in the DNA methylation
between localized early-stage and advanced-stage tumor
groups (Table 3). This suggested that the DNA methyla-
tion changes we detected occurred as early events of
ovarian cancer.
The association between DNA methylation status and
LOH/LOI in ovarian cancers
To determine whether the DNA methylation status in
these DMRs of the imprinted genes acts as an indicator
for potential LOH and/or LOI, we evaluated the
Table 1 Frequencies of LOH, LOI and MOI in human ovarian cancers.
(A) Ovarian cancer tissues
H19/
R sal
IGF2/
Apal
KCNQ1/
Smal
LIT1/
R sal
GTL2/
T aal
PEG1/
AFlll
PEG3/
Mnll
NDN/
Mbol
Heterozygosity 58.5
(41/70)
47.1
(33/70)
55.5
(40/72)
16.2
(12/74)
58.3
(42/72)
50.0
(37/74)
34.2
(25/73)
41.8
(31/74)
LOH 4.8
(2/41)
9.0
(3/33)
5.0
(2/40)
0.0
(0/12)
7.1
(3/42)
8.1
(3/37)
4.0
(1/25)
0.0
(0/31)
LOI 29.2
(12/41)
45.4
(15/33)
12.5
(5/40)
16.6
(2/12)
23.8
(10/42)
45.9
(17/37)
8.0
(2/25)
6.4
(2/31)
MOI 56.0
(23/41)
33.3
(11/33)
77.5
(31/40)
83.3
(10/12)
66.6
(28/42)
45.9
(17/37)
84.0
(21/25)
93.5
(29/31)
ND 9.7
(4/41)
12.1
(4/33)
5.0
(2/40)
0.0
(0/12)
2.3
(1/42)
0.0
(0/37)
4.0
(1/25)
0.0
(0/31)
(B) Cell lines
Heterozygosity 19.0
(4/21)
14.2
(3/21)
33.3
(7/21)
14.39
(3/21)
23.8
(5/21)
42.8
(9/21)
23.8
(5/21)
23.8
(5/21)
LOI 0/4 2/3 3/7 1/3 2/5 3/9 0/5 0/5
MOI 4/4 1/3 4/7 2/3 3/5 6/9 5/5 5/5
Percents of LOH (loss of heterozygosity), LOI (loss of imprinting) and MOI (maintenance of methylation) determined using RFLP analysis of 8 imprinted genes in
74 samples of ovarian cancers and 21 cell lines
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Figure 1 Validation of BPL analysis by comparison with COBRA assay. Examination of the imprinted DMRs by bisulphite PCR Luminex (BPL)
and combined bisulphite PCR restriction analysis (COBRA) assay in DNA samples of ovarian cancer cell lines and normal cells. BPL: y-axis, COBRA:
x-axis. Calculated by Spearman’s rank method. H19 (A) and PEG1 (B).
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Page 3 of 9Table 2 The methylation profiles of 8 imprinted genes by bisulphite PCR Luminex.
Cell Histology H19 GTL2 ZDBF2 PEG1 LIT1 ZAC PEG3 SNRPN
lines BPL COBRA BPL COBRA BPL COBRA BPL COBRA BPL COBRA BPL COBRA BPL COBRA BPL COBRA
CpG
(9,16)
CpG10 CpG
(4,8)
CpG8 CpG
(1,4,5)
CpG4 CpG15 CpG12 CpG
(5,17,19)
CpG16 CpG8 CpG7 CpG20 CpG21 CpG19 CpG19
NC1 N 67.5 34.6 62.2 76.8 66.4 46.2 50.4 38.5 42.7 27.4 62.3 48.4 78.8 67.4 65.3 57.3
NC2 N 55.6 42.7 67.3 82.1 67.9 72.5 54.8 46.2 53.7 37.5 65.2 69.3 65.4 48.9 78.5 67.3
NC3 N 65.8 58.3 81.2 63.5 76.3 82.1 45.3 63.9 26.4 41.6 50.2 72.1 65.8 83.2 56.3 68.2
NC4 N 58.6 72.1 76.4 80.4 80.2 67.2 37.5 58.2 35.8 54.7 47.2 52.8 45.9 58.3 65.2 74.9
OC1 S 10.32 95.4 69.8 53.2 87.3 92.4 83.1 59.2 64.3 48.3 89.5 98.3 74.4 83.2 65.4 58.4
OC2 M 16.8 19.4 61.4 70.5 95.7 97.2 48.8 62.2 62.1 48.0 20.1 10.2 92.1 89.5 29.1 49.7
OC3 S 87.4 93.2 96.3 93.4 83.7 28.6 98.3 90.4 87.4 56.9 87.3 96.5 98.5 96.4 28.4 37.4
OC4 S 42.8 56.8 97.3 93.2 99.3 98.5 0.9 10.4 13.2 17.1 100.9 98.3 48.7 47.2 28.1 24.2
OC5 S 83.4 56.4 89.2 96.6 95.3 72.8 93.2 102.4 28.4 32.6 100.3 91.3 98.8 95.6 54.3 60.4
OC6 E 78.9 72.1 94.3 82.1 38.3 18.3 83.2 68.5 34.2 56.2 85.3 78.9 57.2 97.5 40.5 53.1
OC7 C 0.4 21.3 19.8 29.3 41.7 55.5 60.5 42.0 21.2 11.3 34.5 40.1 90.7 99.0 23.5 52.8
OC8 C 0.1 6.9 6.4 10.5 91.7 87.3 81.8 88.1 35.2 29.1 49.8 53.2 102.1 95.7 21.8 33.2
OC9 S 82.3 54.3 37.4 65.2 22.4 42.8 23.6 18.5 43.7 56.8 69.5 74.9 68.5 90.2 38.2 56.3
OC10 C 83.8 67.8 78.4 65.9 27.9 32.3 63.8 58.7 42.8 60.2 89.9 93.7 59.6 43.9 38.9 71.4
OC11 S 92.4 91.6 17.1 25.0 6.0 18.0 43.2 60.1 18.2 10.0 72.5 58.2 101.4 100.0 75.5 60.5
OC12 S 54.7 53.8 23.7 18.8 48.6 74.3 68.9 58.4 48.3 93.6 98.8 67.4 39.8 73.4 57.1 51.2
OC13 S 80.3 66.2 42.3 40.1 86.0 74.2 93.4 95.2 10.5 8.8 94.4 90.5 102.1 100.0 36.0 39.5
OC14 C 98.1 87.7 67.4 40.3 99.3 90.2 99.6 95.5 12.3 1.6 34.3 41.2 92.1 100.0 38.1 51.2
OC15 C 45.2 45.0 93.0 98.2 99.7 95.3 92.1 94.8 55.0 47.5 27.5 36.4 86.1 97.2 48.7 10.1
OC16 S 36.9 44.6 90.6 92.0 93.0 92.3 100.7 100.0 13.0 6.2 28.9 35.7 93.2 100.0 22.9 17.6
OC17 C 93.8 89.8 61.8 68.3 21.8 22.2 37.9 42.5 48.4 31.8 20.6 31.1 98.3 95.5 0.0 0.2
OC18 C 34.4 46.0 94.5 98.0 95.3 98.0 60.1 73.2 35.2 29.4 17.3 35.0 87.2 100.0 22.7 11.1
OC19 C 67 30.7 47.8 62.1 87.4 85.3 4.1 10.1 11.2 0.0 100.1 100.0 84.6 92.1 30.4 31.4
OC20 M 1.6 42.6 58.1 60.3 62.4 55.2 73.4 81.4 18.3 13.4 49.2 68.2 92.8 98.5 86.7 44.8
OC21 S 8.0 24.5 80.2 87.0 96.6 90.1 77.2 81.2 4.5 8.1 100.5 97.5 107.8 98.2 16.7 16.2
Normal ovarian surface tissues
NT1 (42) 57.5 76.2 43.4 51.2 37.2 65.4 51.4 38.6 49.1 42.3 53.3 41.2 42.1 40.2 521 47.8
NT2 (48) 27.6 25.0 23.6 21.6 46.1 34.5 20.9 34.4 23.1 12.2 5.1 32.3 21.3 20.6 22.1 33.3
NT3 (40) 61.5 31.8 49.9 60.0 50.4 45.0 31.0 42.8 17.1 10.9 48.8 29.4 21.0 33.6 24.3 34.8
NT4 (38) 28.9 25.0 28.4 29.6 46.1 39.3 33.4 47.8 28.8 17.7 67.4 46.1 45.6 33.8 80.5 29.0
NT5 (55) 24.2 26.9 27.2 18.5 33.2 29.0 30.9 48.1 25.1 17.6 10.7 44.5 75.5 40.0 32.3 31.3
NT6 (45) 25.9 22.1 32.2 20.5 46.4 62.5 60.0 40.4 24.1 17.3 25.2 23.4 44.2 69.0 77.4 40.9
NT7 (41) 34.6 24.6 38.0 19.9 49.9 37.4 27.3 46.2 27.7 24.5 21.0 63.1 49.7 53.7 25.6 24.5
Letters in blue and black boldface represent LOH, LOI and MOI, respectively. The Luminex value indicates the average value of DNA methylation
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9association between DNA methylation and LOH and/or
LOI in the IGF2/H19 and PEG1 imprinted domains
separately.
IGF2, which acts as a dominant oncogene, and H19,a
physically and mechanistically linked gene on human
chromosome 11, are reciprocally imprinted. In the pater-
nal allele, H19 DMR is methylated and silenced, whereas
the reciprocally imprinted gene IGF2 is transcribed. By
contrast, in the maternal unmethylated allele, H19 is
expressed but IGF2 is inactivated because of the binding
of the repressor factor CTCF to the unmethylated H19
DMR, which then prevents the H19/IGF2 common
enhancers from activating the IGF2 promoter [19]. IGF2
was found to have high frequencies of both LOH and
LOI in HOC. H19 was also found to have high frequen-
cies of LOI (29.2%, 12/41). Nine of 14 cases with both
IGF2 and H19 heterozygosity showed LOH or LOI of
both genes and only one case had MOI for one of the
two. Thus relaxation of IGF2 and H19 imprinting is fre-
quent. In the IGF2/H19 imprinted region, the samples
with LOH and/or LOI at H19 was more methylated than
those with MOI (Figure 2A, Additional file 3: Table S2).
Table 3 Characterization of methylation profiles of the imprinted genes in DNA of ovarian cancers.
(A) Histology
H19 GTL2 ZDBF2 PEG1 LIT1 ZAC PEG3 SNRPN
Normal (n = 7) 34.3 ± 11.8 34.7 ± 9.5 44.2 ± 6.6 30.7 ± 15.1 27.9 ± 12.6 33.1 ± 5.8 42.8 ± 18.5 44.9 ± 25.3
Cancer (n = 74) 41.7 ± 17.2 39.6 ± 18.8 43.8 ± 6.6 45.9 ± 15.5* 27.9 ± 14.1 41.1 ± 6.4 41.1 ± 14.1 42.8 ± 12.9
Serous (n = 36) 47.6 ± 18.9 38.8 ± 22.0 42.0 ± 18.5 48.9 ± 14.7* 28.8 ± 9.8 42.7 ± 16.6 40.9 ± 14.8 39.3 ± 12.2
Mucinous (n = 9) 36.0 ± 15.0 35.2 ± 19.2 36.8 ± 14.0 47.1 ± 20.0 34.7 ± 21.4 42.2 ± 5.9 31.2 ± 11.2 42.7 ± 17.8
Endometrioid (n = 10) 37.9 ± 14.8 30.7 ± 14.4** 57.8 ± 19.8 45.5 ± 13.7 22.8 ± 13.0 37.5 ± 11.5 46.8 ± 15.9 41.4 ± 10.8
Clear (n = 18) 45.6 ± 20.2 54.0 ± 20.1 39.7 ± 20.8 42.2 ± 13.8 25.5 ± 12.4 40.2 ± 16.1 45.7 ± 14.5 47.8 ± 11.1
(B) Progress (Staging)
Localized (I, II) (n = 29) 38.8 ± 14.9 40.8 ± 20.4 46.7 ± 19.4 47.8 ± 17.1 30.4 ± 16.1 41.0 ± 11.9 42.8 ± 17.8 44.2 ± 12.9
Advanced (III, IV) (n = 45) 47.8 ± 19.6 41.3 ± 22.2 41.9 ± 19.2 45.9 ± 13.7 26.2 ± 10.0 41.1 ± 16.8 41.2 ± 12.8 40.9 ± 12.6
(C) Age
Under 44 years (n = 17) 46.7 ± 18.5 35.3 ± 21.0 42.0 ± 20.4 48.9 ± 13.5 24.2 ± 11.7 39.9 ± 12.3 44.7 ± 14.3 36.3 ± 10.7
45-55 years (n = 29) 39.9 ± 14.7 47.2 ± 23.0 45.8 ± 17.5 46.9 ± 15.0 30.1 ± 14.8 38.9 ± 15.5 41.9 ± 15.8 45.4 ± 11.1
Over 56 years (n = 32) 47.4 ± 21.2 38.4 ± 18.1 42.2 ± 21.1 45.1 ± 16.2 28.2 ± 10.9 44.1 ± 15.7 40.8 ± 14.9 42.5 ± 14.5
The values in the list are mean ± SD (standard deviation). Statistically significant differences between groups are presented as *P < 0.05, and **P < 0.01 by
ANOVA
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Figure 2 The association between hypermethylation and LOH/LOI.( A )IGF2/H19 DMR. The rate of DNA methylation (mean ± SD) of cases
with LOH/LOI of either IGF2 or H19 and MOI were compared. For this analysis, one case which H19 was MOI and IGF2 was LOI, was removed.
(B) PEG1 DMR. Statistically significant differences between groups are analyzed with ANOVA followed with multiple comparison method (Tukey’s
HSD test), presented as the P-value (*P < 0.01). Norm: Normal ovarian tissues.
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finding [20]. PEG1 was reported to be a TSG and was
also found to have high frequency of LOH/LOI in HOC.
We also found that the samples with LOH/LOI at PEG1
were more methylated than those with MOI with statisti-
cal significance (Figure 2B, Additional file 3: Table S2).
Discussion
Alterations in DNA methylation are the most common
molecular alterations in human malignancies. Detection of
the aberrant DNA methylation associated with cancer-
related genes is a promising approach to improve cancer
prevention, diagnosis and treatment options. Bisulphite
modification is a prerequisite for most popular techniques
aiming at detecting changes in methylation, but has been
limited by throughput capacity. In this study, we used a
high-throughput methylation detection method to analyze
DNA methylation at 8 imprinted DMRs in epithelial ovar-
ian cancer. We found that the PCR-Luminex method pre-
cisely quantified the methylation status of specific DNA
regions in somatic cells and was also relatively rapid, eco-
nomical and easy to use.
In the epithelial ovarian cancers, the frequency of LOI
was higher than that of LOH. In particular, LOI was most
frequent at PEG1, IGF2 and H19 DMRs. The frequency,
extent of changes in DNA methylation and loci affected
varied considerably among the samples. Generally, we
found that DNA methylation at imprinted DMRs was
increased in both cell lines and primary material. Impor-
tantly, we showed that gain of DNA methylation in the
imprinted DMRs was apparent in tumors with LOI, espe-
cially at PEG1 and H19. We also found DNA methylation
changes in the absence of LOI. In other words, there were
changes in DNA methylation at DMRs that were not asso-
ciated with biallelic gene expression.
When we examined the clinical characteristics of the
tumors, we found no significant differences in the fre-
quency of LOI and aberrant DNA methylation between
the localized early-stage and advanced-stage tumor groups.
This suggested that the changes we identified occurred as
a relatively early event of HOC. In general, the PEG1 and
H19 DMRs appeared to be particularly prone to errors.
This is similar to the previous findings in human sperm
from subfertile men [21]. In ZDBF2 and GTL2 DMRs,
aberrant DNA methylation occurred in HOC. As with
H19, these DMRs are paternally methylated DMRs in
somatic cells. In childhood cancers such as retinoblastoma,
Wilms’ tumor and osteosarcoma, changes primarily occur
on the paternal allele first, followed by a second hit on the
maternal allele [5,6,22]. Similarly, methylation of paternally
imprinted DMR in normal somatic cells might be a first
hit and cause ovarian carcinogenesis. These observations
suggest a role for altered genomic imprinting in the malig-
nant transformation process.
A previous report had demonstrated the association
between the abnormal genomic imprinting of H19 and
IGF2 expression [20]. The aberrant hypermethylation in
the CTCF binding site of the H19 gene was seen in the
cases of HOC and correlated with IGF2 LOI. Our results
for H19 were similar to those reported findings. The most
frequent methylation error in HOC was seen in the PEG1
DMR. In our previous report, we showed that demethyla-
tion of PEG1 was present in growing oocytes from supero-
vulated infertile women [23]. This PEG1 DMR may be
especially vulnerable to errors. LOI of PEG1 has subse-
quently also been implicated in the aetiology of lung ade-
nocarcinomas, breast and colon cancer.
HOC is the leading cause of death from gynecologic
malignancies because the majority of cases are not
detected until the disease is well advanced. Our under-
standing of cancer as a clonal genetic disease has led to
the identification of genetic alterations in many cancer
types. However, ovarian cancer remains less well charac-
terized. Only a few TSG genes acting in a recessive man-
ner have been identified as somatically mutated or
methylated in ovarian cancer, including TP53 (48%) [24],
PTEN (21% in the endometrioid subtype) [25], RB1 (7-
10%) [26], and CDKN2A (79% in the mucinous subtype)
[27]. Biomarkers provide useful tools in screening for can-
cer and are now emerging as highly informative for moni-
toring disease status [28]. They can improve early
detection and also the quality of life of patients with ovar-
ian cancer. DNA methylation offers an additional tool that
can be used in combination with other markers [29]. In
addition, it has been established that DNA methylation
biomarkers are present in patient serum and other body
fluids [30]. To date, several methylated genes have been
found to be highly prognostic for specific cancers, includ-
ing those of the prostate [31], breast [32] and lung [33].
Although some methylated markers such as RASSF1A and
GSTP1 have potential as prognostic indicators individually
[34,35], ‘methylation signature’ panels could be much
more informative [36] and accurate for monitoring cancer
progression. Methylation patterns have previously been
suggested to be tumor and stage specific [37]. Our work
demonstrates that there is aberrant DNA methylation at
several imprinted DMRs inH O Cw i t hc h a n g e sa tPEG1
and H19 being the most frequent and earliest alterations
detected.
Conclusion
This is the first study reporting the use of PCR-Luminex
for identification of prognostic panels of DNA methylation
biomarkers for cancer. We believe that this approach is
amenable to the classification of clinically relevant methy-
lation patterns in a wide variety of tumors (and other
pathologies) linked to the aberrant DNA methylation of
imprinted DMRs. This BPL method may be sufficiently
Hiura et al. BMC Medical Genomics 2012, 5:8
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methylation in the very small number of circulating cancer
cells found in blood and urine samples from patients.
Methods
Ovarian cancer cell lines and primary culture of surface
epithelial cells
Twenty-one HOC cell lines were used in our study: 10
from serous adenocarcinoma (OVCAR3, CAOV3, JHOS2,
HTOA, SKOV3, OV90, JHOS3, JHOS4, KF, MH), 2 from
mucinous adenocarcinoma (OMC3, MCAS), 8 from clear
cell adenocarcinoma (ES2, JHOC5, TOV21G, JHOC7,
JHOC8, KM, HAC2, RMG) and 1 from endometrioid ade-
nocarcinoma (TOV112D). The sources of these cells and
culture methods were as described previously [38,39].
Four primary cultures of normal human ovarian surface
epithelial (OSE1-4) cells were initiated from surface scrap-
ings of normal ovaries as described [40].
Ovarian cancer tissue(s)
Seventy-four primary HOC tissues (36 serous, 9 mucinous,
10 endometrioid, 18 clear cell, and 1 other, Table 3) were
obtained from patients presenting at our hospital. The
mean ± standard deviation (SD) of the patients’ ages for
normal ovary and ovarian cancer tissues were 44.1 ± 6.6
and 52.9 ± 7.3, respectively. Seven specimens of normal
ovarian surface epithelium were obtained from patients
with benign non-ovarian disease. Histological diagnoses
and clinical staging were performed according to the
International Federation of Gynecologists and Obstetri-
cians (FIGO) criteria. The numbers of cancer patients
with localized tumors (stage I and II) and advanced tumor
(stages III and IV) were 29 and 45, respectively. The sam-
ples were stained with hematoxylin and eosin to demon-
strate > 85% of epithelial tumor cells. DNA and RNA were
then extracted from the remaining samples [38]. DNA was
also extracted from peripheral blood in matched patients.
The study was performed after obtaining the patients’
informed consent and with approval from the institutional
ethics committee of the Tohoku University Graduate
School of Medicine.
Analysis of loss of heterozygosity (LOH) and loss of
imprinting (LOI)
PCR was performed on patient blood and tumor genomic
DNA using the primer sequences summarized in Addi-
tional file 4: Table S3. A PCR reaction mix containing
0.5 μM of each primer set, 200 μM dNTPs, 1 × PCR buf-
fer, and 1.25U of EX Taq Hot Start DNA Polymerase
(Takara Bio, Tokyo, Japan) in a total volume of 20 μl was
used. The following PCR program was used: 1 minute of
denaturation at 94°C followed by 35 cycles of 30 seconds
at 94°C, 30 seconds at 60°C and 30 seconds at 72°C and a
final extension for 5 minutes at 72°C. PCR products were
digested by unique polymorphic enzymes to identify sam-
ples that were heterozygous for a single nucleotide poly-
morphism (SNP). For samples found to be heterozygous
for a SNP, RNA was prepared from matched tumors, fol-
lowed by reverse transcription-PCR (RT-PCR) and by
restriction digestion [41-48]. The digested PCR products
were electrophoresed on 2% agarose gel.
DNA methylation analysis
Bisulphite PCR-Luminex (BPL) methylation analysis was
performed as described [18]. PCR primers sets, biotiny-
lated at their 5’-end, were designed for gene amplification.
PCR reaction mix contained 0.2 μMp r i m e r ,0 . 2m M
dNTPs, 1 × PCR buffer (50 mM KCl, 10 mM Tris-HCl,
pH 8.3). 3 mM MgCl2, 2% dimethyl sulfoxide (DMSO),
0.625U Taq DNA Polymerase (Roche, Tokyo, Japan) and
100-200 ng of bisulphite treated DNA in a total volume of
25 μl. PCR conditions: 40 cycles of 95°C for 20 s/60°C for
30 s/72°C for 30 s using a GeneAmp 9700 thermal cycler
(Applied Biosystems, CA, USA). Oligonucleotide probe
sequences (Additional file 2: Table S1 in Ref 18) were
synthesized and covalently bound to carboxylated fluores-
cent microbeads using ethylene dichloride (EDC). These
oligonucleotide-labeled microbeads (oligobeads) were
mixed together to make an oligobeads mixture of 100 oli-
gobeads/μl and hybridized to the 5’-biotin-labeled PCR
amplicons in a total volume of 50 μl per well in a 96-well
plate by adding 5 μl of the appropriate oligobead mixture
and 5 μl of the PCR amplicons to 40 μl of hybridization
buffer. This reaction mixture was first denatured at 95°C
for 2 min and then hybridized at 48°C for 30 min. After
hybridization, the oligobeads were washed in 100 μlo f
PBS-Tween and pelleted by microcentrifugation. Pelleted
oligobeads were reacted with a 70 μl aliquot of a 100 ×
diluted solution of SA-PE in PBS-Tween. Hybridized
amplicons were labeled with SA-PE at 48°C for 15 min.
Reaction outcomes were measured by the Luminex 100
flow cytometer. Methylation assays were additionally per-
formed for each DMR using the conventional bisulphite
treatment PCR methylation assay and combined bisulphite
PCR restriction analysis (COBRA) as described previously
[21].
Statistical analyses
Differences between groups were analysed by analysis of
variance, followed by Post-hoc, Tukey’s HSD test. Statis-
tical analyses were performed using the JMP (v9.0.0,
SAS Institute Japan, Tokyo, Japan). Statistically signifi-
cant differences between groups are presented as *P <
0.05, and **P < 0.01. Results for BPL and COBRA were
compared using Spearman’s rank method and Pearson’s
product-moment correlation coefficients.
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Additional file 1: Table S1 The list of LOH, LOI and MOI in HOC.
LOH, LOI and MOI determined using RFLP analysis of 8 imprinted genes
are summarized. NC: Normal cells (NC1-4). NT: Normal ovarian tissues
(NT1-7). CC: Cancer cell lines (CC1-21). CT: Cancer tissue (CT1-74).
Additional file 2: Figure S1 Validation of BPL analyses by
comparison with COBRA assay. Examination of the imprinted DMRs by
bisulphite PCR Luminex (BPL) and combined bisulphite PCR restriction
analysis (COBRA) assay in DNA samples of ovarian cancer cell lines and
normal cells. BPL: y-axis, COBRA: x-axis. The number was calculated by
Spearman’s rank method. GTL2 (C), ZDBF2 (D), LIT1 (E), ZAC (F), PEG3 (G)
and SNRPN (H).
Additional file 3: Table S2 Sequences of PCR primers and restriction
enzymes used for PCR-RFLP analysis.
Additional file 4: Table S3 Bisulphite PCR-Luminex and COBRA
methylation profiles of the eight imprinted DMRs in the DNA of
human ovarian cancer cells and normal ovarian tissues. Numbers in
blue and black boldface indicate LOI and MOI, respectively. Luminex
values indicate average methylation values at the sites tested. NC:
Normal cells (OSE1, OSE2, OSE3, OSE4). CC: Cancer cell lines (CC1:
OVCAR3, CC2: OMC3, CC3: CAOV3, CC4: JHOS2, CC5: HTOA, CC6:
TOV112D, CC7: ES2, CC8: JHOC5, CC9: SKOV3, CC10: TOV21G, CC11: OV90,
CC12: JHOS3, CC13: JHOS4, CC14: JHOC7, CC15: JHOC8, CC16: KF, CC17:
KM, CC18: HAC, CC19: RMG, CC20: MCAS, CC21: MH. NT: Normal ovarian
tissues (NT1-NT7). N: Normal, S: Serous adenocarcinoma, M: Mucinous
adenocarcinoma, E: Endometrioid carcinoma, C: Clear cell carcinoma.
Abbreviations
BPL: Bisulphite PCR-Luminex; COBRA: Combined bisulphite PCR restriction
analysis; DMR: Differentially methylated region; FIGO: International Federation
of Gynecologists and Obstetricians; HOC: Human ovarian cancer; LOH: Loss
of heterozygosity; LOI: Loss of imprinting; MOI: Maintenance of imprint; ND:
Not determined; PCR: Polymerase chain reaction; QOL: Quality of Life; RFLP:
Restriction fragment length polymorphism; RT-PCR: Reverse transcription-
PCR; SNP: Single nucleotide polymorphism.
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